Presidential Session

[PS-3] Neoadjuvant nivolumab（N）+chemo（C）and adjuvant N in resectable NSCLC：CheckMate 77T Japanese data

^○Fumihiro Tanaka¹, Yasutaka Watanabe², Shunichi Sugawara³, Jiro Okami⁴, Satoshi Muto⁵, Morihito Okada⁶, Yoshitsugu Horio⁷, Masahiro Tsuboi⁸, Yuki Sato⁹, Kazuya Takamochi¹⁰, Hidehito Horinouchi¹¹, Yuichi Tambo¹², Masahiro Seike¹³, Kyoichi Okishio¹⁴, Cinthya Coronado Erdmann¹⁵, Padma Sathyanarayana¹⁵, Stephanie Meadows Shropshire¹⁵, Hiroyuki Ito¹⁶ (1.University Of Occupational And Environmental Health Hospital, Kitakyushu, Japan, 2.Saitama Cancer Center, Saitama, Japan, 3.Sendai Kousei Hospital, Sendai, Japan, 4.Osaka International Cancer Institute, Osaka, Japan, 5.Fukushima Medical University Hospital, Fukushima, Japan, 6.Hiroshima University Hospital, Hiroshima, Japan, 7.Aichi Cancer Center Hospital, Nagoya, Japan, 8.National Cancer Center Hospital East, Kashiwa, Japan, 9.Kobe City Medical Center General Hospital, Kobe, Japan, 10.Juntendo University Hospital, Tokyo, Japan, 11.National Cancer Center Hospital, Kashiwa, Japan, 12.Kanazawa University Hospital, Kanazawa, Japan, 13.Nippon Medical School Hospital, Tokyo, Japan, 14.National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan, 15.Bristol Myers Squibb, Princeton, NJ, USA, 16.Kanagawa Cancer Center, Yokohama, Japan)